A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Perez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estevez, Peter A. Van Dam, Sherko Kummel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-PadillaFlorian D. Vogl, Dalila Sellami, Carlos L. Arteaga

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint Dive into the research topics of 'A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)'. Together they form a unique fingerprint.

Medicine & Life Sciences